No deal brexit’s impact on the pharmaceutical and medical devices industries: guidance from the ema and the european commission
In relation to the above, the European Medicines Agency and the European Commission are providing guidance on Brexit for pharmaceutical companies, including launching a dedicated page on their website.
On February 1, 2019, the European Commission published an updated Q&A document on the topic of the UK’s withdrawal from the EU with regard to industrial products, including medical devices, and medical products for human and veterinary use, which can be viewed at the following links:
These FAQs address the scenario in which the UK will leave the EU without any transition period or without any other arrangements being put in place, and therefore having a potentially disruptive impact on businesses. In this case, the UK will immediately become a third country from the EU’s perspective.